90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

Radioimmunotherapy (RIT) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies RIT was represented by yttrium‐90‐ibritumomab tiuxetan ((90)Y‐IT). Independently by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei, Beatrice, Pellegrini, Cinzia, Pulsoni, Alessandro, Annechini, Giorgia, De Renzo, Amalia, Stefoni, Vittorio, Broccoli, Alessandro, Gandolfi, Letizia, Quirini, Federica, Tonialini, Lorenzo, Morigi, Alice, Argnani, Lisa, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924367/
https://www.ncbi.nlm.nih.gov/pubmed/26990782
http://dx.doi.org/10.1002/cam4.684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924367/
https://www.ncbi.nlm.nih.gov/pubmed/26990782
http://dx.doi.org/10.1002/cam4.684

Ejemplares similares